GEMP - Gemphire Therapeutics - Stock Forecast

Coverage Performance Price Targets & Ratings Chart Insider Trading

with an average price target of $7.27. This is a potential upside of $7.27 (0%) from yesterday's end of day stock price of $0.

Gemphire Therapeutics's activity chart (see below) currently has 4 price targets and 3 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 54.17% with an average time for these price targets to be met of 78.5 days.

Most recent stock forecast was given by MATTHEW ANDREWS from on 13-Aug-2018. First documented stock forecast 30-Aug-2016.

Best performing analysts who are covering GEMP - Gemphire Therapeutics:

Matthew Andrews Yasmeen Rahimi

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

2

$-5.5 (-73.33%)

18

5 years 8 months 6 days ago

3/4 (75%)

$0.34 (20.48%)

130

Hold

2

$-5.5 (-73.33%)

30

5 years 8 months 9 days ago

1/3 (33.33%)

$14.2 (165.52%)

27

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is GEMP (Gemphire Therapeutics) average time for price targets to be met?

On average it took 78.5 days on average for the stock forecasts to be realized with a an average price target met ratio 54.17

Which analyst has the current highest performing score on GEMP (Gemphire Therapeutics) with a proven track record?

MATTHEW ANDREWS

Which analyst has the current lower performing score on GEMP (Gemphire Therapeutics) with a proven track record?

YASMEEN RAHIMI

Which analyst has the most public recommendations on GEMP (Gemphire Therapeutics)?

Matthew Andrews has 7 price targets and 9 ratings on GEMP

Which analyst is the currently most bullish on GEMP (Gemphire Therapeutics)?

Yasmeen Rahimi with highest potential upside - $-5.5

Which analyst is the currently most reserved on GEMP (Gemphire Therapeutics)?

Matthew Andrews with lowest potential downside - -$5.5

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?